Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9 studies found for:    DIPAK
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Lanreotide to Treat Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Lanreotide
2 Not yet recruiting Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Condition: Permanent Atrial Fibrillation
Interventions: Drug: Bisoprolol;   Drug: Digoxin
3 Recruiting WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW - ACS)
Condition: Acute Coronary Syndrome
Intervention: Drug: Aspirin
4 Active, not recruiting Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma
Conditions: Lung Cancer;   Lymphoma;   Non-small Cell Lung Cancer;   Non-Hodgkin Lymphoma;   Mediastinal Lymphadenopathy
Intervention: Other: Cohort
5 Recruiting Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Study
Condition: Cardiovascular Disease
Intervention:
6 Terminated A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
Condition: Seasonal Allergic Conjunctivitis to Ragweed
Intervention: Drug: Olopatadine
7 Active, not recruiting Alternative Risk Markers in Coronary Artery Disease (ARMCAD)
Condition: Coronary Artery Disease
Intervention:
8 Enrolling by invitation Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure
Condition: Heart Failure
Interventions: Drug: Beta blocker;   Other: Placebo
9 Recruiting To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
Condition: Acne Vulgaris
Interventions: Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;   Drug: DUAC® Gel;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.